ATRS - Antares Pharma EPS beats by $0.26 beats on revenue; reaffirms guidance
Antares Pharma (ATRS): Q4 GAAP EPS of $0.30 beats by $0.26.Revenue of $44.1M (+16.5% Y/Y) beats by $1.79M.FY2021 guidance: revenue in the range of $175M-200M, which represents a 17% to 34% year-over-year growth rate vs consensus of $184.94M.Press Release
For further details see:
Antares Pharma EPS beats by $0.26, beats on revenue; reaffirms guidance